COVID-19 >> New Drug Activity & VACCINE TRACKING!!

[Anonymous]

And?

Stay tuned.

[Frood]

I'm already tuned.

[Bricktop]

Ditto. I've used natural Chinese remedies in Singapore. No harm done.



But that was for a flu, not a lethal ailment.

Like oat bran and preventing heart disease.

Oat bran is not sold as a medicinal treatment that "cures" or "remedies" ailments.

[Anonymous]

Ditto. I've used natural Chinese remedies in Singapore. No harm done.



But that was for a flu, not a lethal ailment.

Like oat bran and preventing heart disease.

Oat bran is not sold as a medicinal treatment that "cures" or "remedies" ailments.

But, cereal makers will say their cereals are made with oat bran that has been proven to reduce the risk of heart disease or shit like that. Bottom line is that manufacturers' environmental, safety, and health claims are bullshit. We know that, but as I say it don't hurt to use em.

[Anonymous]

New Drug for Seriously Ill COVID-19 Patients Shows Promise Under Right to Try Act



ZYESAMI, developed by the Radnor, Pennsylvania-based pharmaceuticals company, currently is being tested with patients as part of the approval process of the U.S. Food and Drug Administration (FDA). The company hopes to earn emergency-use authorization (EUA) that would allow widespread use of the drug in the treatment of COVID-19.



The hospital reported that 16 of the 19 patients treated with ZYESAMI for COVID-19 respiratory failure "survived the ICU," NRx announced. ZYESAMI is the brand name of aviptadil, a synthetic version of a natural chemical made in the human body called human vasoactive intestinal polypeptide.



The hospital's report said there were no serious adverse events associated with the use of the drug, according to the company's statement. Patients were treated during the Omicron surge at the first onset of respiratory failure, after first trying remdesivir and other approved therapies.

https://www.theepochtimes.com/new-drug-for-seriously-ill-covid-19-patients-shows-promise-under-right-to-try-act_4247983.html?utm_source=morningbriefnoe&utm_campaign=mb-2022-02-02&utm_medium=email&est=6UiTXF19wqTxSMx2bIMHMjoxsqixEGCGciFKLCDA62OcIXlMnG%2BO5PIW%2Bhs1FWbXfQ%3D%3D">https://www.theepochtimes.com/new-drug- ... bXfQ%3D%3D">https://www.theepochtimes.com/new-drug-for-seriously-ill-covid-19-patients-shows-promise-under-right-to-try-act_4247983.html?utm_source=morningbriefnoe&utm_campaign=mb-2022-02-02&utm_medium=email&est=6UiTXF19wqTxSMx2bIMHMjoxsqixEGCGciFKLCDA62OcIXlMnG%2BO5PIW%2Bhs1FWbXfQ%3D%3D

[Anonymous]

New Drug for Seriously Ill COVID-19 Patients Shows Promise Under Right to Try Act



ZYESAMI, developed by the Radnor, Pennsylvania-based pharmaceuticals company, currently is being tested with patients as part of the approval process of the U.S. Food and Drug Administration (FDA). The company hopes to earn emergency-use authorization (EUA) that would allow widespread use of the drug in the treatment of COVID-19.



The hospital reported that 16 of the 19 patients treated with ZYESAMI for COVID-19 respiratory failure "survived the ICU," NRx announced. ZYESAMI is the brand name of aviptadil, a synthetic version of a natural chemical made in the human body called human vasoactive intestinal polypeptide.



The hospital's report said there were no serious adverse events associated with the use of the drug, according to the company's statement. Patients were treated during the Omicron surge at the first onset of respiratory failure, after first trying remdesivir and other approved therapies.

https://www.theepochtimes.com/new-drug-for-seriously-ill-covid-19-patients-shows-promise-under-right-to-try-act_4247983.html?utm_source=morningbriefnoe&utm_campaign=mb-2022-02-02&utm_medium=email&est=6UiTXF19wqTxSMx2bIMHMjoxsqixEGCGciFKLCDA62OcIXlMnG%2BO5PIW%2Bhs1FWbXfQ%3D%3D">https://www.theepochtimes.com/new-drug- ... bXfQ%3D%3D">https://www.theepochtimes.com/new-drug-for-seriously-ill-covid-19-patients-shows-promise-under-right-to-try-act_4247983.html?utm_source=morningbriefnoe&utm_campaign=mb-2022-02-02&utm_medium=email&est=6UiTXF19wqTxSMx2bIMHMjoxsqixEGCGciFKLCDA62OcIXlMnG%2BO5PIW%2Bhs1FWbXfQ%3D%3D

I would try it if I was in ICU with COVID.

[Anonymous]

Natural immunity still proves to be superior.



Natural Immunity to COVID-19 Detected at 20 Months After Infection: Study



Protection against the virus that causes COVID-19 among the recovered was detected by researchers at 20 months post-infection, adding to the body of evidence that such protection, known as natural immunity, is long-lasting.



Researchers found antibodies against the SARS-CoV-2 spike protein receptor-binding domain (RBD) in 99 percent of study participants who tested positive for COVID-19, with some having had the illness as long as 20 months prior.



The researchers, led by Dr. Dorry Segev, the director of the Epidemiology Research Group in Organ Transplantation at Johns Hopkins University, put out a call for unvaccinated, healthy adults in the fall of 2021 and divided them into three groups. The first group consisted of 295 participants who had test-confirmed COVID-19 infections in the past; the second consisted of 275 participants who believed they recovered from COVID-19 but did not get a test; the third consisted of 246 people who did not think they ever had COVID-19 and had never tested positive.

https://www.theepochtimes.com/natural-immunity-to-covid-19-detected-at-20-months-after-infection-study_4256564.html?utm_source=morningbriefnoe&utm_campaign=mb-2022-02-05&utm_medium=email&est=khu26TI6iUNtjkEG1J0uYHMWUCN%2BiWjsgQBVhJ5sVlri9mExByya7d8MOXgyQCIwGg%3D%3D">https://www.theepochtimes.com/natural-i ... IwGg%3D%3D">https://www.theepochtimes.com/natural-immunity-to-covid-19-detected-at-20-months-after-infection-study_4256564.html?utm_source=morningbriefnoe&utm_campaign=mb-2022-02-05&utm_medium=email&est=khu26TI6iUNtjkEG1J0uYHMWUCN%2BiWjsgQBVhJ5sVlri9mExByya7d8MOXgyQCIwGg%3D%3D

[Frood]

https://www.bitchute.com/video/G6AdUcTOE86J/">https://www.bitchute.com/video/G6AdUcTOE86J/



Jabbed!

[Anonymous]

Authorized FDA COVID-19 treatments.



AUTHORIZED

REMDESIVIR

Cost: ~$3,300

EUA Date: April 16, 2020

Pharmaceutical company Gilead Sciences was informed by the FDA on April 16, 2020, that its antiviral drug remdesivir would receive an EUA for treating COVID-19 in hospitalized patients. The drug was in the process of several clinical trials at the time. On Oct. 22, 2020, remdesivir became the only drug to receive full FDA approval for COVID-19 treatment. The treatment group had a median time to recovery of 10 days, while the placebo group had a time of 15 days. At 29 days, when the monitoring for the study concluded, the treatment group still had a somewhat higher recovery rate, but the difference was no longer statistically significant—the drug didn't look particularly helpful in keeping the patients alive.



CONVALESCENT PLASMA

Cost: ~$5,000–$10,000

EUA Date: Aug. 23, 2020

The FDA granted an EUA for convalescent plasma, an unapproved treatment using antibodies from people who've recovered from COVID-19, on Aug. 23, 2020. Current studies indicate the treatment may have some positive effect on reducing hospitalizations, but the initial EUA only applied to already hospitalized patients, where studies report underwhelming results. The treatment is in limited supply and costs thousands of dollars.



BARICITINIB

Cost: ~$4,800

EUA Date: Nov. 19, 2020

On Nov. 19, 2020, the FDA gave an EUA to baricitinib, an FDA-approved arthritis drug, to treat some COVID-19 patients, such as those on ventilators or requiring supplemental oxygen. The initial clinical trials indicated improved results, including lower mortality, in those receiving the treatment, though the results were barely

within the range of statistical significance.

   Baricitinib, sold under the brand name Olumiant, has a cash price of about $87 per 1 milligram tablet, according to Drugs.com. The FDA recommends 4 milligrams a day for 14 days with lower doses for some patients. The regular treatment course thus adds up to more than $4,800.



MONOCLONAL ANTIBODY THERAPY

Cost: ~$1,000–$2,000

EUA Date: Nov. 21, 2020

On Nov. 21, 2020, the FDA authorized the first monoclonal antibody therapy, a combination of casirivimab and imdevimab, for people with "mild to moderate"

COVID-19 "who are at high risk for progression to severe COVID-19." The treatment costs more than $2,000, and

the supply is limited.

Research indicates the treatment is effective at reducing mortality, but a December study found it may no longer work on the Omicron variant (pdf). The FDA noted the EUA doesn't apply to any area where Omicron is the likely variant, which is currently the entire United States.

On May 26, 2021, the FDA gave an EUA to sotrovimab, another monoclonal antibody treatment, also for mild-to-moderate COVID-19 cases at risk of progression to severe disease. It has so far only been examined in a handful of studies, though the early treatment results were positive. One clinical trial showed the hospitalization rate cut by somewhere between 45 and 93 percent. The treatment appears to still work against Omicron, but it costs over $2,000, according to Drugs.com.



TOCILIZUMAB

Cost: ~$3,200

EUA Date: June 24, 2021

The FDA authorized tocilizumab, another FDA-approved anti-arthritis drug, to treat some COVID-19 patients, such as those on ventilators or requiring supplemental oxygen, on June 24, 2021. The authorization was based on four clinical trials. Three smaller ones showed no statistically significant improvement in recovery time or mortality compared to placebo. One larger one in the UK showed 31 percent mortality in the treatment

group versus 35 percent in the "usual care" group, a difference near the edge of statistical significance.

   Tocilizumab, sold under brand name Actemra, has a cash price of about $120 per milliliter containing 20 milligrams of the drug, according to Drugs.com. The FDA-recommended adult dosing of one infusion of 8 milligrams per kilogram of patient weight adds up to about $3,200 for a 150-pound patient.



EUA Date: Dec. 8, 2021

EVUSHELD

Cost: ~$10

The FDA gave an EUA for Evusheld,

a nonapproved monoclonal antibody treatment consisting of tixagevimab

co-packaged with cilgavimab, on Dec. 8, 2021. It costs about $10 per infusion, according to Drugs.com, but the FDA only allows its use as a prophylactic for immunocompromised patients or those allergic to the COVID-19 vaccines.

Research indicates it still has some

effect on Omicron.



ASTRAZENECA

PAXLOVID

Cost: ~$530

EUA Date: Dec. 22, 2021

The FDA gave on Dec. 22, 2021, an EUA to Paxlovid, a combination of nonapproved nirmatrelvir and ritonavir marketed by Pfizer, for treatment of "mild-to-moderate" COVID-19 in people with "high risk for progressing to severe COVID-19."

   There have only been a few studies on Paxlovid, but so far it appears to significantly lower hospitalization and mortality risk. The drug isn't yet available. The U.S. government has agreed to buy 10 million treatment courses at a price of about $530 per course.



MOLNUPIRAVIR

Cost: ~$700

EUA Date: Dec. 23, 2021

The FDA gave on Dec. 23, 2021, an EUA to Molnupiravir, a nonapproved antiviral marketed by Merck, for the same use as Paxlovid, except it could also be used in people "for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate."

   The drug went through a handful of clinical trials. The largest one, with about 1,400 participants, showed mortality risk cut by somewhere between 14 and 99 percent. Relative risk of hospitalization or death was cut by somewhere between 1 and 51 percent.



Not Authorized



IVERMECTIN

Cost: ~$100–$1,000

Ivermectin is one of the most extensively studied drugs as a potential COVID-19 therapeutic. There have been more than 70 studies in 26 countries involving over 85,000 participants. Most of the studies show positive effects, especially in early treatment.

Only a minority of the studies were randomized, controlled clinical trials (RCT). Most of the RCTs were small, only involving up to a few hundred patients. One exception is an RCT in Singapore with over 3,000 low-risk patients showing a nearly 50 percent reduced risk of symptomatic infection when a combination of drugs, including ivermectin, hydroxychloroquine, povidone-iodine, zinc, and vitamin C, was used as a prophylactic. When 19 of the RCTs were combined into a meta-analysis last year, the data indicated risk of death reduction of somewhere between 38 to 85 percent.

   Ivermectin costs about $100 to $1,000 per treatment course, depending on the dosage and length of treatment. It has been used for decades as an antiparasitic and for other ailments.



HYDROXYCHLOROQUINE

Cost: ~$7

EUA Date: March 28, 2020 (revoked on June 15, 2020)

Hydroxychloroquine was the first to receive an EUA for treating COVID-19, on March 28, 2020. The authorization, however, only applied to hospitalized patients. While the drug has antiviral properties, that appears to be of little use to hospitalized patients since the disease at that point tends to proceed to its inflammatory phase and it's then too late to block the virus. The FDA revoked the EUA on June 15, 2020.

   By now, hydroxychloroquine has been studied even more extensively than ivermectin. Its bane has been flawed research. The drug's theoretical mechanism of action is slowing viral replication. As such, its effect would be expected early on in the disease. The existing research, over 300 studies involving more than 400,000

patients, shows mixed results. Only a few dozen studies examined early treatment, showing statistically significant positive effects on mortality. So far, there has been only one early treatment RCT with over 1,000 participants. It looked at 1,360 U.S. health care workers and showed a 25 percent lower risk of symptomatic COVID-19 in the half that received the drug as a prophylactic. The results lacked statistical significance. When all the prophylactic RCTs were combined in a meta-analysis published last month, it showed that risk

of a positive case was cut by 28 percent.

   Hydroxychloroquine costs about $7 per treatment course and has been used for decades to prevent malaria and treat

other diseases.



FLUVOXAMINE

Cost: ~$45

Fluvoxamine, an antidepressant that costs about $45 per treatment course, hasn't been studied as extensively as hydroxychloroquine or ivermectin, but the available research indicates an impact on

hospitalization and mortality. One RCT

with about 1,500 participants showed a statistically significant reduction in hospitalization or extended emergency room observation by about 30 percent.



BASIC COMPOUNDS

Cost: ~$3.50

Image

Some basic compounds such as zinc and vitamins A and D have shown positive results, but suffer a dearth of robust RCTs. For vitamin D and zinc, if the available RCTs are pooled together in a meta-analysis, they add up to a statistically significant impact on mortality or other

indicators. There's also the question, though, of whether taking the compounds helps in general, or whether people deficient in the compounds have a harder time fighting off the infection and the positive results come at least partly from mitigating the deficiency.



OTHERS

Cost: ~$10–$230

A number of other, less researched treatments have shown some positive results, including povidone-iodine ($10),

lactoferrin ($60), budesonide ($50), colchicine ($115–$230), favipiravir ($20), and metformin ($13).

[cc]

Some basic compounds such as zinc and vitamins A and D have shown positive results, but suffer a dearth of robust RCTs. For vitamin D and zinc, if the available RCTs are pooled together in a meta-analysis, they add up to a statistically significant impact on mortality or other

indicators. There's also the question, though, of whether taking the compounds helps in general, or whether people deficient in the compounds have a harder time fighting off the infection and the positive results come at least partly from mitigating the deficiency.

It makes sense that being strong in these going in is a serious advantage. They are the very elements I have been taking daily (along with a cpl of other items recommended by many docs (like quercetin) in a bit above normal dosage since this started. Blood tests are a good idea to make sure not too far over the line. D well over the normal as it is major in keeping immune system strong

I would up them a bit more if I caught it & sneak some in my suitcase if hospitalized

[Anonymous]

I have been taking multis since I took up health and fitness in a big way seventeen years ago. I have been taking extra D and zinc.

[cc]

I have been taking extra D and zinc.

Good plan under current situation .. D helps strengthen immune system & zink works directly against the virus if contracted

[Frood]

With Quercetin...

[Anonymous]

With Quercetin...

Quercetin is most commonly used for conditions of the heart and blood vessels and to prevent cancer. It is also used for arthritis, bladder infections, and diabetes, but there is no strong scientific evidence to support most of these uses.There is also no good evidence to support using quercetin for COVID-19.

[cc]

Not meaning to be argumentative, but "early in the game" .. I did see many  good reports on Quercetin  and in fact reports of many or most hospitals  using it .. saying it greatly helps get zink into action



That was a while ago now .. Have not checked on it lately



I have used  it from very early in the game .. say summer or so of 2021